Pump thrombosis in the Thoratec HeartMate II device: An update analysis of the INTERMACS Registry.
نویسندگان
چکیده
BACKGROUND Pump thrombosis in durable continuous-flow pumps is a barrier to long-term mechanical circulatory support. Earlier Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) data identified an increasing risk of pump thrombosis in recent years with the HeartMate II (HMII) left ventricular assist device. The current analysis examines pump thrombosis in the patient cohort extended through June 2014. METHODS The INTERMACS identified 9,808 adult patients from 144 institutions receiving a primary HMII implant between April 2008 and June 30, 2014. Pump thrombosis was identified at time of explant, transplant or death. Risk factors for pump thrombosis were examined by multivariable analysis in the hazard function domain. The association between pump thrombosis and implant year was modeled in the hazard domain. RESULTS Parametric hazard modeling of thrombosis by year of implant identified an increasing risk of pump thrombosis from 2009 through 2013, followed by a decrease in the risk during the first half of 2014, which was most apparent during the first 3 months post-implant. Risk factors for pump thrombosis included younger age (p < 0.001), higher body mass index (p = 0.02), history of non-compliance (p = 0.004), severe right heart failure (p = 0.02), later date of implant (p < 0.0001), and elevated lactate dehydrogenase during the first month post-implant (p < 0.0001). Subsequent pump thrombosis was more likely if the initial pump exchange indication was pump thrombosis (p < 0.0001). CONCLUSIONS The small, but progressive increase in the incidence of pump thrombosis observed between 2010 and 2013 with the HMII pump had reversed somewhat in the first half of 2014. Identification of marked elevation of lactate dehydrogenase during the first month offers an opportunity for early intervention strategies.
منابع مشابه
Reliability of the Thoratec HeartMate II flow measurements and alarms in the presence of reduced or non-existent flow.
INTRODUCTION The Thoratec Corporation has over 10,000 patients registered as recipients of the HeartMate II left ventricular assist device (LVAD) worldwide. Although it has undoubtedly prolonged the lifespan of heart failure patients, the most recognized risk associated with these devices is the development of thrombus. In the presence of a small or developing clot, the HeartMate II display mod...
متن کاملWhat is the truth behind pump thrombosis in the HeartMate II device? A National Heart, Lung, and Blood Institute perspective based on data from the Interagency Registry for Mechanically Assisted Circulatory Support.
The clinical community faces major issues in caring for the 100,000 to 300,000 advanced heart failure patients in the United States. For these patients, left ventricular assist devices (LVADs) may provide life-saving options for use as destination therapy or as a bridge to heart transplantation. Emerging and changing patterns of adverse events in continuous-flow LVADs present challenges to opti...
متن کاملHigh fidelity computational simulation of thrombus formation in Thoratec HeartMate II continuous flow ventricular assist device
Continuous flow ventricular assist devices (cfVADs) provide a life-saving therapy for severe heart failure. However, in recent years, the incidence of device-related thrombosis (resulting in stroke, device-exchange surgery or premature death) has been increasing dramatically, which has alarmed both the medical community and the FDA. The objective of this study was to gain improved understanding...
متن کاملThe Heartmate Risk Score predicts morbidity and mortality in unselected left ventricular assist device recipients and risk stratifies INTERMACS class 1 patients.
OBJECTIVES This study evaluated the Heartmate Risk Score (HMRS) and its potential benefits in clinical practice. BACKGROUND The HMRS has been shown to correlate with mortality in the cohort of patients enrolled in the Heartmate II trials, but its validity in unselected, "real world" populations remains unclear. METHODS This study identified a cohort of 269 consecutive patients who received ...
متن کاملChronic LDH Elevation after Left Ventricular Assist Device Implantation
A 61-year-old woman who underwent HeartMate II left ventricular assist device placement for non-ischemic cardiomyopathy developed elevated lactate dehydrogenase within two weeks after implantation. After eight months of observation and several hospital admissions during which there was no evidence of pump thrombosis, she presented with clinically manifest hemolysis. During pump exchange there w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
دوره 34 12 شماره
صفحات -
تاریخ انتشار 2015